Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset

Blood (2019) 134 (Supplement_1): 2130.

https://doi.org/10.1182/blood-2019-125640

Published: 2019

Journal Articles

MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial

Blood (2019) 134 (Supplement_1): 4321.

https://doi.org/10.1182/blood-2019-125134

Published: 2019

Journal Articles

Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients

Blood (2019) 134 (Supplement_1): 4322.

https://doi.org/10.1182/blood-2019-124645

Published: 2019

Journal Articles

Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics

Blood (2019) 134 (Supplement_1): 4357.

https://doi.org/10.1182/blood-2019-122657

Published: 2019

Journal Articles

IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies

Elisa Bergaggio, Chiara Riganti, Giulia Garaffo, Nicoletta Vitale, Elisabetta Mereu, Cecilia Bandini, Elisa Pellegrino, Verdiana Pullano, Paola Omedè, Katia Todoerti, Luciano Cascione, Valentina Audrito, Anna Riccio, Antonio Rossi, Francesco Bertoni, Silvia Deaglio, Antonino Neri, Antonio Palumbo, Roberto Piva

Blood (2019) 133 (2): 156–167.

https://doi.org/10.1182/blood-2018-05-850826

Published: 2019

Includes: Supplemental data

Journal Articles

Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies

Roberto Mina, MD, Alessandra Larocca, MD, Maria Teresa Petrucci, MD, Gianluca Gaidano, MD, Stelvio Ballanti, MD, Pellegrino Musto, MD, Massimo Offidani, MD, Paola Omedé, Giulia Benevolo, MD, Alessandra Malfitano, Piero Galieni, MD, Michele Cavo, MD, Tommaso Caravita di Toritto, MD, Vittorio Del Fabro, MD, Vittorio Montefusco, MD, Antonio Palumbo, MD, Mario Boccadoro, MD, Sara Bringhen, MD

Blood (2018) 132 (Supplement 1): 3240.

https://doi.org/10.1182/blood-2018-99-112075

Published: 2018

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2018) 132 (Supplement 1): 121.

https://doi.org/10.1182/blood-2018-99-112093

Published: 2018

Journal Articles

Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs

Luisa Giaccone, Andrea Evangelista, Francesca Patriarca, Roberto Sorasio, MD, Massimo Pini, MD, Fabrizio Carnevale Schianca, MD, Moreno Festuccia, Lucia Brunello, Francesco Zallio, MD, Enrico Maffini, Paola Omedè, PhD, Sara Bringhen, MD, Nicola Mordini, MD, Renato Fanin, MD, Massimo Massaia, MD, Antonio Palumbo, MD, Giovannino Ciccone, MDPhD, Mario Boccadoro, MD, Benedetto Bruno, MD PhD

Blood (2016) 128 (22): 3469.

https://doi.org/10.1182/blood.V128.22.3469.3469

Published: 2016

Journal Articles

An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials

Blood (2016) 128 (22): 3336.

https://doi.org/10.1182/blood.V128.22.3336.3336

Published: 2016

Journal Articles

Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features

Blood (2016) 128 (22): 5625.

https://doi.org/10.1182/blood.V128.22.5625.5625

Published: 2016

Journal Articles

Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy

Stefania Oliva, MD, Manuela Gambella, Alessandra Larocca, Stefano Spada, Eleonora Marzanati, Barbara Mantoan, Sara Grammatico, Concetta Conticello, MD, Barbara Gamberi, Massimo Offidani, Anna Marina Liberati, Chiara Pautasso, Paola Omedé, Antonio Palumbo, MD, Mario Boccadoro

Blood (2016) 128 (22): 4409.

https://doi.org/10.1182/blood.V128.22.4409.4409

Published: 2016

Journal Articles

A Comparative Study of Biosimilar Filgrastim Versus Originator G-CSF for CD34+ Cells Mobilization and Autografting in Hematological Malignancies

Lucia Brunello, Luisa Giaccone, Maria Josè Fornaro, Matilde Scaldaferri, Valter Redoglia, Paola Omedè, PhD, Moreno Festuccia, Giovannino Ciccone, Massimo Massaia, MD, Dario Ferrero, Federica Cavallo, Antonio Palumbo, MD, Francesco Cattel, Andrea Evangelista, Mario Boccadoro, MD, Benedetto Bruno, MD PhD

Blood (2016) 128 (22): 2183.

https://doi.org/10.1182/blood.V128.22.2183.2183

Published: 2016

Journal Articles

Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity

Davine Hofste op Bruinink, MD MSc, Stefania Oliva, MD, Lucie Rihova, PhD, Bronno van der Holt, PhD, Milena Gilestro, BSc, Jeroen G. te Marvelde, BSc, Pavla Vsianska, MSc, Alexander Schmitz, PhD, Helle Høholt, BSc, Hans Erik Johnsen, MDDMSc, Mario Boccadoro, MD, Roman Hajek, MD, Pieter Sonneveld, MD PhD, Antonio Palumbo, MD, Paola Omedè, PhD, Vincent H.J. van der Velden, PhD

Blood (2016) 128 (22): 2072.

https://doi.org/10.1182/blood.V128.22.2072.2072

Published: 2016

Journal Articles

HIF-1α Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target

Blood (2016) 128 (22): 305.

https://doi.org/10.1182/blood.V128.22.305.305

Published: 2016

Journal Articles

Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway

Riccardo Bomben, Simone Ferrero, Michele Dal Bo, Tiziana D'Agaro, Alessandro Re, Andrea Evangelista, Angelo Michele Carella, Alberto Zamò, Umberto Vitolo, MD, Paola Omedè, Chiara Rusconi, Luca Arcaini, Luigi Rigacci, Stefano Luminari, MD, Sergio Cortelazzo, Marco Ladetto, Valter Gattei, MD

Blood (2015) 126 (23): 701.

https://doi.org/10.1182/blood.V126.23.701.701

Published: 2015

Journal Articles

Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study

Blood (2015) 126 (23): 1760.

https://doi.org/10.1182/blood.V126.23.1760.1760

Published: 2015

Journal Articles

The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance

Valentina Griggio, Ms, Candida Vitale, MD, Chiara Riganti, MD, Joanna Kopecka, PhD, Michele Dal Bo, Davide Rossi, MD PhD, Gabriele Pozzato, MD, Luca Laurenti, MD, Francesco Zallio, MD, Monia Marchetti, MD PhD, Marina Ruggeri, Paola Omedè, Giovanni Del Poeta, Pr, MD, Valter Gattei, MD, Gianluca Gaidano, MD PhD, Mario Boccadoro, MD, Massimo Massaia, MD, Marta Coscia, MD PhD

Blood (2015) 126 (23): 2925.

https://doi.org/10.1182/blood.V126.23.2925.2925

Published: 2015

Journal Articles

Highly Sensitive Droplet Digital PCR for MYD88 L265P Mutation Detection and Minimal Residual Disease Monitoring in Waldenström Macroglobulinemia

Daniela Drandi, Elisa Genuardi, Paola Ghione, Daniele Grimaldi, Barbara Mantoan, Marina Ruggeri, Daniela Barbero, Luigia Monitillo, Marika Vasta, Eleonora Marzanati, Giulia Verardo, Paola Omedè, Federica Cavallo, Mario Boccadoro, MD, Marco Ladetto, Simone Ferrero

Blood (2015) 126 (23): 2645.

https://doi.org/10.1182/blood.V126.23.2645.2645

Published: 2015

Journal Articles

Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients

Lenka Kubiczkova-Besse, Lenka Sedlarikova, Fedor Kryukov, Lenka Radova, PhD, Jana Nekvindova, Pavel Nemec, Daniela Drandi, Simona Caltagirone, Paola Omedè, PhD, Marta Krejci, As Prof, MD PhD, Zdenek Adam, prof, MD PhD, Ludek Pour, Doc, MD PhD, Sabina Sevcikova, PhD, Antonio Palumbo, MD, Mario Boccadoro, Roman Hajek, Prof, MD PhD

Blood (2014) 124 (21): 2043.

https://doi.org/10.1182/blood.V124.21.2043.2043

Published: 2014

NARROW

Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset

MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial

Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients

Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics

IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies

Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs

An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials

Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features

Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy

A Comparative Study of Biosimilar Filgrastim Versus Originator G-CSF for CD34+ Cells Mobilization and Autografting in Hematological Malignancies

Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity

Extracellular Vesicles as Potential Biomarker for Acute Graft-Versus-Host-Disease

HIF-1α Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target

Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway

Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study

The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance

Highly Sensitive Droplet Digital PCR for MYD88 L265P Mutation Detection and Minimal Residual Disease Monitoring in Waldenström Macroglobulinemia

Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only